Who is sponsoring NCT05491330?

NCT05491330 is sponsored by Genuine Research Center, Egypt.

What drugs are being tested in NCT05491330?

Interventions in NCT05491330: Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose), Nirmatrelvir 150 mg + Ritonavir 100 mg (test), Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose).

Is NCT05491330 still recruiting?

NCT05491330 is currently completed. Last updated 18 January 2023.

Last reviewed 2023-01-18 · How we verify

NCT05491330

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bioequivalence Study of Nirmatrelvir & Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)

Completed Phase 1 Last updated 18 January 2023

What this trial tests

Phase 1 trial testing Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose) in Healthy in 28 participants. Completed in 27 October 2022.

Timeline

21 August 2022

Primary endpoint
4 September 2022

27 October 2022

Quick facts

Lead sponsor	Genuine Research Center, Egypt
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	other
Enrollment	28
Start date	21 August 2022
Primary completion	4 September 2022
Estimated completion	27 October 2022
Sites	1 location across Egypt

Drugs / interventions tested

Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference first dose) — full drug profile →
Nirmatrelvir 150 mg + Ritonavir 100 mg (test) — full drug profile →
Nirmatrelvir 150 mg + Ritonavir 100 mg (Reference second dose) — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Genuine Research Center, Egypt — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Comparative randomized, single dose, three-way, three-sequence, two treatment, partial replicate, crossover, open-label study to determine the bioequivalence of Nirmatrelvir \& Ritonavir From Copaxid 150 +100 mg Tablets (Eva Pharma, Egypt) Versus Paxlovid 150 + 100 mg Film Coated Tablets (Pfizer Europe, Belgium)

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Genuine Research Center, Egypt trials

Trials by the same sponsor.

NCT05876585 — Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard o · Phase 3 · not yet recruiting
NCT05880056 — Study of Bisoprolol (Nerkardou - Nerhadou International) 5 and 10 mg Oral Dissolvable Film (ODF) Treatment in Egyptian P · Phase 4 · recruiting
NCT05798715 — Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 m · Phase 1 · completed
NCT05855187 — Bioequivalence Study of Modafinil From Bravamax 200 mg Scored Tablets (Chemipharm Pharmaceutical Industries, Egypt) Vers · Phase 1 · completed
NCT05804721 — Bioequivalence Study of Aripiprazole From Apipe 10 mg Orally Disintegrating Tablets (Man. by: P&C Labs (Pellets & CR Pro · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05491330 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Genuine Research Center, Egypt
Last refreshed: 18 January 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05491330.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing